Corvus Pharmaceuticals, Inc. Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent
Corvus Pharmaceuticals, Inc. (CRVS) had Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent of $3.00 thousand as of 2018-06-30, per its 10-Q filed 2018-08-02.
Discontinued › Notes › Compensation Related Costs
us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent · last filed 2019-03-07
- 2018-06-30: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $3.00K.
- 2018-03-31: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $7.00K.
- 2017-12-31: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $11.00K.
- 2017-09-30: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $14.00K.
| Period end | Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent |
|---|---|
| 2018-06-30 | $3.00K 10-Q · filed 2018-08-02 |
| 2018-03-31 | $7.00K 10-Q · filed 2018-05-03 |
| 2017-12-31 | $11.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $14.00K 10-Q · filed 2017-11-02 |
| 2017-06-30 | $21.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $28.00K 10-Q · filed 2017-05-04 |
| 2016-12-31 | $35.00K 10-K · filed 2018-03-01 |
| 2016-09-30 | $43.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $52.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $58.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $68.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |